Abstract:The menace of progressive cardiac systolic dysfunction and sudden cardiac death(SCD)still hover threateningly over the patient with heart failure.Despite available phagnlacological treatment is utilized.it is still proven lowly effective in the prevention of SCD caused by fatal ventricular arrhythmia.Data from AHA indicated that evaluation and management of patients at risk for SCD (primary prevention)has higher efficacy in reducing mortality than secondary prevention.Unfortunately,present risk stratifiers,such as HRV,QT interval dispersion and late potential testing,does not offer accurate and timely alarms in primary prevention of SCD.Nowadays,randomized muhicenter trials(AVID、CASH、CIDS)and clinical practice have proven t11at conventional implantable cardioverter defibrillator(ICD)implantation has become the standard even optimal treatment in the secondary prevention for SCD.Is primary prophylactic ICD therapy for SCD in patients with heart failure eriective?Positive results from MADIT Ⅱ trial seems give us a promising fotare.It indicated that comparing with pharmacological treatment.ICD has substantial advances in lowering all cause mortality for patients after infarction with LVEF＜0.30 even without history of tachycardia.As with the MADIT Ⅱ trial.subsequent DEFINITE trial and SCD-HeFT trial also confirmed ICD.is an effective treatment.and increased survival in selected patients.Based on results of these trials.ACC/AHA/HRS revised the content of latest clinical guideline.It expand the indication of ICD implantation for potentially eligible patients are screened on the basis of LVEF＜0.30 or＜0.35 and anticipated survival with good functional capacity bevond 1 year.The report in present press bv GUO Hong-xia.XU Wei,et al also demonstrated that ICD implantation is a safe and effective therapy in primary prevention of SCD in 22 patients with heart failure.It may be the first report about evaluation of primary prevention of SCD by ICD in China.It could suggest that 1CD become a commonplace management for primary prophylactic therapy.Hence,it implicates that prophylactic ICD therapy could be upgraded to first line strategy for SCD.In addition.in view of the fact that CRT is also deftnite preventive solution for progression of heart failure.we suggest that making CRT-D as optimal strategy for primary prevention of SCD.

Prevention of Sudden Cardiac Death after Revascularization for Coronary Heart Disease

For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death

Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review

Arrhythmias and Sudden Cardiac Death

Stable Coronary Artery Disease: Who Finally Benefits from Coronary Revascularization in the Modern Era? The ISCHEMIA and Interim ISCHEMIA-EXTEND Analysis

From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond

Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy: impact on primary prevention of sudden cardiac death

Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death: a single center experience

[Effect of spinal cord stimulation on myocardial ischemia/infarction].

Primary Prevention of Sudden Cardiac Death Using Implantable Cardioverter Defibrillators

Revascularization for Patients With Heart Failure With Preserved Ejection Fraction and Coronary Artery Disease

Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease

Myocardial Revascularization in Heart Failure: A State-of-the-Art Review

Sudden Cardiac Death in Hypertrophic Cardiomyopathy:Hig-risk Factors and Prevention

Implantable cardioverter defibrillator is primary prophylactic therapy for sudden cardiac death in patients with heart failure

Cardiomyopathy and Sudden Cardiac Death: Bridging Clinical Practice with Cutting-Edge Research

Development of The Non-revascularization Therapy for Acute Coronary Syndrome

Prophylactic ICD implantation for primary prevention of sudden cardiac death

Optional Revascularization Strategies for Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease

Current Problems and Research Progress of Risk Stratification of Sudden Cardiac Death after Myocardial Infarc-tion

Opportunities for sudden death prevention: Directions for new clinical and basic research